The Atlantic published an essay on June 21, 2026, titled "I'd Rather Risk Cancer Than See AI Move This Fast," by an assistant professor of computer science at UC Berkeley. The author recounts meeting an early mentor who later co-founded Anthropic and identifies that mentor as Dario Amodei, citing his 2024 essay "Machines of Loving Grace" - which predicted superhuman AI could compress a century of scientific progress and potentially reduce cancer mortality by 95 percent. The author reports carrying a genetic mutation that confers a very high cancer risk and says she would personally benefit if AI cured cancer, yet the essay argues for slowing the pace of AI development. The piece frames this as a moral dilemma between rapid biomedical gains and broader societal risks, as reported by The Atlantic.
What happened
The Atlantic published an essay on June 21, 2026, titled "I'd Rather Risk Cancer Than See AI Move This Fast," by an assistant professor of computer science at UC Berkeley. The author recounts meeting an idealistic researcher who later co-founded Anthropic and identifies him as Dario Amodei, per the essay. The Atlantic piece says Amodei's 2024 essay "Machines of Loving Grace" predicted that superhuman AI could compress a century of scientific progress into a single decade and potentially reduce cancer mortality by 95 percent. The author reports that she carries a genetic mutation that gives her a very high risk of breast, ovarian, and other cancers and states she would benefit if AI cured cancer - while nevertheless arguing for slowing AI progress.
Editorial analysis - technical context
Industry observers often note a persistent tradeoff between accelerated AI-driven discovery and unanticipated systemic harms. Slower, staged deployment of capabilities is a recurring policy proposal in safety debates that aims to create time for risk assessment, governance, and robust evaluation of medical and non-medical impacts. For practitioners, this tension manifests as harder questions about release criteria for models used in high-stakes domains such as drug discovery and diagnostics.
Context and significance
The essay places a personal moral dilemma into a broader public conversation about AI governance and biomedical innovation. Public opinion pieces that combine first-person stakes with references to high-profile AI figures like Dario Amodei and firms such as Anthropic tend to shape how policymakers and institutional review boards frame acceptable risk timelines. This is part of an ongoing cultural and regulatory debate about how fast to deploy increasingly capable systems that affect health, safety, and institutions.
What to watch
- •Regulatory and legislative activity addressing AI pace and clinical applications, including proposed guardrails for model deployment in healthcare.
- •Publication and replication patterns for AI-driven biomedical claims, especially those that move quickly from preprint to commercial use.
- •Statements or proposals from prominent AI labs on staged deployment or external verification processes for high-stakes domains.
Scoring Rationale #
Well-placed personal essay in a major magazine that sharpens the AI safety-versus-biomedical-progress debate, with a credentialed author (UC Berkeley CS) and direct references to Anthropic's Dario Amodei. Important for governance discourse but does not introduce new technical results or regulatory action; scored as solid opinion with practitioner relevance rather than a policy event.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
250 free problems · No credit card
See all Health & Insurance problems